{
    "Trade/Device Name(s)": [
        "GEM Premier 5000"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K160402",
    "Predicate Device Reference 510(k) Number(s)": [
        "K133407",
        "K142898"
    ],
    "Regulatory Class": "II, I(Reserved)",
    "Product Code(s)": [
        "CGA",
        "KHP",
        "MQM"
    ],
    "Summary Letter Date": "December 8, 2016",
    "Summary Letter Received Date": "December 9, 2016",
    "Submission Date": "December 8, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 862.1450",
        "21 CFR 862.1113"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Lactic acid test system",
        "Bilirubin (total and unbound) in the neonate test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose",
        "Lactate",
        "Total bilirubin"
    ],
    "Specimen Type(s)": [
        "Venous heparinized whole blood",
        "Arterial heparinized whole blood",
        "Capillary heparinized whole blood"
    ],
    "Specimen Container(s)": [
        "Heparinized syringe",
        "Capillary tube"
    ],
    "Instrument(s)/Platform(s)": [
        "GEM Premier 5000 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometry",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Quantitative analysis"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "System",
        "Cartridge",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for the GEM Premier 5000 analyzer for quantitative measurement of glucose, lactate, and total bilirubin in heparinized whole blood at point-of-care and central laboratory settings.",
    "Indications for Use Summary": "The GEM Premier 5000 provides rapid quantitative measurement of glucose, lactate, and total bilirubin in venous, arterial, and capillary heparinized whole blood to aid in diagnosing a patient's metabolite balance, including carbohydrate metabolism disturbances, acid-base status, and risk of hyperbilirubinemia in neonates.",
    "fda_folder": "Clinical Chemistry"
}